Carmen Herrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carmen Herrero has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Pilar Iranzo
Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
2 shared publications A Azon Masoliver
Servicio de Dermatología, Hospital Clínic i Provincial, Barcelona
1 shared publicationA Llambrich
Department of Dermatology, Hospital de Manacor, Mallorca, Spain
1 shared publicationA. Guilabert
1 shared publication- Cristina Carrera
Melanoma Unit, Dermatology Department, Hospital Clínic De Barcelona, IDIBAPS, Universitat De Barcelona, Barcelona, Spain
1 shared publication D Romero
Department of Dermatology, Hospital Clinic, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 1 January 2008
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 99 (8) , 598-607
Diagnosis and Treatment of Livedo Reticularis on the Legs
- 1 January 2008
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 99 (8) , 598-607
Open AccessDiagnosis and Treatment of Livedo Reticularis on the Legs
- 1 January 2007
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (1) , 136-137
Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide
- 1 January 2007
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (1) , 136-137
Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide
- 16 October 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (10) , 1350-1352
Erythema multiforme presenting as cholestatic acute hepatitis caused by Epstein‐Barr virus
- 16 October 2006
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (10) , 1350-1352
Erythema multiforme presenting as cholestatic acute hepatitis caused by Epstein‐Barr virus
- Open Access
- 19 July 2002
- Published by Springer Nature in Environmental Health
- Vol. 1 (1) , 1
Serum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene
Porphyria cutanea tarda (PCT) is caused by hexachlorobenzene (HCB) in several species of laboratory mammals, but the human evidence is contradictory. In a study among adults of a population highly exposed to HCB (Flix, Catalonia, Spain), the prevalence of PCT was not increased. We aimed at analysing the association of individual urinary porphyrins with the serum concentrations of HCB and other organochlorine compounds in this highly exposed population. A cross-sectional study on total porphyrins was carried out in 1994 on 604 inhabitants of the general population of Flix, older than 14 years. Of them, 241 subjects (comprising a random sample and the subgroup with the highest exposure) were included for the present study. The porphyrin profile was determined by high-pressure liquid chromatography. Serum concentrations of HCB, as well as common organochlorine compounds, were determined by gas chromatography coupled to electron capture detection. Coproporphyrin I (CPI) and coproporphyrin III (CPIII) were the major porphyrins excreted, while uroporphyrins I and III were only detected in 2% and 36% of the subjects respectively, and heptaporphyrins I and III in 1% and 6%, respectively. CPI and CPIII decreased with increasing HCB concentrations (p < 0.05). This negative association was not explained by age, alcohol, smoking, or other organochlorine compounds. No association was found between uroporphyrin I and III excretion, nor heptaporphyrin excretion, and HCB. CPIII increased with smoking (p < 0.05). HCB exposure in this highly exposed population did not increase urinary concentrations of individual porphyrins.
- 19 July 2002
- Published by Springer Nature in Environmental Health
- Vol. 1 (1) , 1
Open AccessSerum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene
Porphyria cutanea tarda (PCT) is caused by hexachlorobenzene (HCB) in several species of laboratory mammals, but the human evidence is contradictory. In a study among adults of a population highly exposed to HCB (Flix, Catalonia, Spain), the prevalence of PCT was not increased. We aimed at analysing the association of individual urinary porphyrins with the serum concentrations of HCB and other organochlorine compounds in this highly exposed population. A cross-sectional study on total porphyrins was carried out in 1994 on 604 inhabitants of the general population of Flix, older than 14 years. Of them, 241 subjects (comprising a random sample and the subgroup with the highest exposure) were included for the present study. The porphyrin profile was determined by high-pressure liquid chromatography. Serum concentrations of HCB, as well as common organochlorine compounds, were determined by gas chromatography coupled to electron capture detection. Coproporphyrin I (CPI) and coproporphyrin III (CPIII) were the major porphyrins excreted, while uroporphyrins I and III were only detected in 2% and 36% of the subjects respectively, and heptaporphyrins I and III in 1% and 6%, respectively. CPI and CPIII decreased with increasing HCB concentrations (p < 0.05). This negative association was not explained by age, alcohol, smoking, or other organochlorine compounds. No association was found between uroporphyrin I and III excretion, nor heptaporphyrin excretion, and HCB. CPIII increased with smoking (p < 0.05). HCB exposure in this highly exposed population did not increase urinary concentrations of individual porphyrins.
- 1 October 1999
- Vol. 17 (8) , 382-5
[Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients].
Checking the first 70 low risk liver transplantation performed in our hospital, who did not receive prophylaxis for Cytomegalovirus, we found that the incidence of Cytomegalovirus-infection and Cytomegalovirus-disease were 47% and 16% respectively. For this reason we started a prospective, open clinical study, to address the safety of acyclovir prophylaxis in low-risk liver transplant patients. Seventy patients did not receive acyclovir. Fifty patients received oral acyclovir during 3 months (800-3,200 mg/day). The occurrence of Cytomegalovirus infection was not modified (40%) but Cytomegalovirus disease decreased dramatically (4%, p < 0.01) during the first year after transplantation. Acyclovir was well tolerated. The incidence of leukopenia and renal failure were similar in both groups. Acyclovir did not improved the global survival of patients. Thus, oral acyclovir does not reduce Cytomegalovirus infection although it is efficient and safe in the prevention of Cytomegalovirus disease in low-risk liver transplantation, and prevents Herpes-simplex and Varicela-zoster symptomatic disease in this group of patients.
- 1 October 1999
- Vol. 17 (8) , 382-5
[Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients].
Checking the first 70 low risk liver transplantation performed in our hospital, who did not receive prophylaxis for Cytomegalovirus, we found that the incidence of Cytomegalovirus-infection and Cytomegalovirus-disease were 47% and 16% respectively. For this reason we started a prospective, open clinical study, to address the safety of acyclovir prophylaxis in low-risk liver transplant patients. Seventy patients did not receive acyclovir. Fifty patients received oral acyclovir during 3 months (800-3,200 mg/day). The occurrence of Cytomegalovirus infection was not modified (40%) but Cytomegalovirus disease decreased dramatically (4%, p < 0.01) during the first year after transplantation. Acyclovir was well tolerated. The incidence of leukopenia and renal failure were similar in both groups. Acyclovir did not improved the global survival of patients. Thus, oral acyclovir does not reduce Cytomegalovirus infection although it is efficient and safe in the prevention of Cytomegalovirus disease in low-risk liver transplantation, and prevents Herpes-simplex and Varicela-zoster symptomatic disease in this group of patients.
- 1 January 1989
- Vol. 17 (5) , 315-6
[Familial sarcoidosis].